이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. (BONE DINIRRA)

2026년 9월 28일 업데이트: University Hospital, Strasbourg, France

Osteosarcomas, like other primitive bone tumors, remain hard-to-treat malignancies, especially after failure of first-line treatments. Multiple mechanisms are initiating or rendering bone tumor cells resistant to the chemotherapies leading to the drastic reduction of treatment possibilities in case of relapses. Among the list of extra-tumoral mechanisms enabling this cancer cell resistance, hypoxia and tumor-associated macrophage modulation seem to be in the top ranks. Based on that, we generated by the past tumor data where the study of hypoxic biomarkers' expressions and the presence of protumoral macrophages were influencing the prognosis of osteosarcoma patients. In fact, the association of HIF1 hyperexpression and a high number of M2 phenotype macrophages (e.g., protumoral cells) were predictive markers of the worst outcome. We recently redone this translational approach in other bone tumors like Ewing sarcomas (EWS) showing the same prognostic tendency. Furthermore, a past pediatric phase I trial, named RAPIRI, targeting both mTor and HIF1, with combination of Sirolimus and Irinotecan, was able to provide in the relapsing bone cancers a partial response or stable disease in more than 50% of patients and particularly in patients with blood concentrations of Sirolimus between 5 and 15 µg/L. To go further and understand the potential links between macrophages and hypoxic resistant tumors, recent preliminary exploration, with an immunofluorescent assessment targeting GD2 expression on tumor cell membranes, was underlining osteosarcomas but also EWS with standard fusions and CIC-DUX4 cancers as hyperexpressing cancers for this disialoganglioside. The cell-surface molecule was highly expressed in 22 out of 32 diagnostic samples (unpublished data). This glycosphingolipid usually presenting a restricted pattern of expression on normal tissues seems to be frequently hyperexpressed in some cancers and therefore amenable to targeting by the monoclonal antibody Dinutuximab beta. The anti-GD2 effect of this drug relies on complement and immune effector cells to mediate cancer cell killing. Recent and unpublished preclinical data in our Lab (UMR-CNRS7021, Strasbourg) envisioned the proof-of-concept combining Sirolimus, Irinotecan and Dinutuximab beta in osteosarcoma models and afford sustainable results to conclude to a clear efficiency of this triple combination stopping completely osteosarcoma cell proliferation and reducing drastically their invasion in microenvironment. Gathering all those prerequisite data and, as the monoclonal therapeutic antibody (Dinutuximab beta) now is extensively evaluated in clinics in multiple indications (e.g., neuroblastomas, Ewing sarcomas and other sarcomas), we propose here a phase I/II trial with this combination of treatments targeting hypoxia and GD2 in bone tumors focusing on relapsing bone tumors with endpoints determining accurate dose to give to patients and its efficacy at 16 weeks of treatment.

연구 개요

상태

아직 모집하지 않음

연구 유형

중재적

등록 (추정된)

89

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Bordeaux, 프랑스
        • Oncologie Médicale-Institut Bergonié
        • 연락하다:
        • 수석 연구원:
          • Maud TOULMONDE
      • Bordeaux, 프랑스
        • Unité d'Hémato-Oncologie Pédiatrique (UHOP) -CHU de Bordeaux - GH Pellegrin
        • 연락하다:
        • 수석 연구원:
          • Jordane CHAIX
      • Lille, 프랑스, 59000
        • Oncologie - Unité pédiatrique Centre Oscar Lambret
        • 연락하다:
        • 수석 연구원:
          • Cyril LERVAT
      • Lyon, 프랑스
        • Institut d'hématologie et d'oncologie Pédiatrique iHOPE
        • 연락하다:
        • 수석 연구원:
          • Nadège CORRADINI
      • Lyon, 프랑스
        • Oncologie médicale adulte- Centre Léon Bérard
        • 연락하다:
        • 수석 연구원:
          • Mehdi BRAHMI
      • Marseille, 프랑스
        • Hématologie, Immunologie et Oncologie Pédiatrique (HIOP), CHU Timone Enfants,
        • 연락하다:
        • 수석 연구원:
          • Gabriel REVON RIVIERE
      • Nancy, 프랑스
        • Onco-hématologie pédiatrique- CHRU NANCY-BRABOIS
        • 연락하다:
        • 수석 연구원:
          • Ludovic MANSUY
      • Paris, 프랑스
        • Oncologie Médicale - Institut Curie
        • 연락하다:
        • 수석 연구원:
          • Valérie LAURENCE
      • Paris, 프랑스
        • Oncopédiatrie-SIREDO - Institut Curie
        • 연락하다:
        • 수석 연구원:
          • Sarah WINTER
      • Strasbourg, 프랑스, 67000
        • Oncologie médicale, Hôpitaux Universitaires de Strasbourg
        • 연락하다:
        • 수석 연구원:
          • Justine GANTZER
      • Strasbourg, 프랑스, 67098
        • Onco-hématologie pédiatrique- Hôpitaux Universitaires de Strasbourg
        • 연락하다:
        • 수석 연구원:
          • Natacha ENTZ WERLE, MD, PhD
      • Toulouse, 프랑스
        • Unité d'Hématologie Immunologie Oncologie Pédiatrique, CHU Toulouse
        • 연락하다:
        • 수석 연구원:
          • Marie-Pierre CASTEX

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

6년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Biopsy proven osteosarcomas, Ewing sarcomas, other primitive bone cancers (chondrosarcomas, CIC-DUX4 bone sarcomas, Ewing-like tumors with rare fusions). Patients with relapsed refractory tumors are eligible whether the target tumor(s) is(are) considered resectable or unresectable at study entry, provided that immediate surgery is not considered medically required or immediately feasible. For tumors considered potentially resectable, resectability will be reassessed after study treatment, particularly at week 16, within a multidisciplinary tumor board.

  2. Refractory or relapsed sarcomas with no brain metastasis.

  3. 1 to 3 prior treatments for metastatic or locally advanced sarcoma.

  4. Age ≥ 6 and ≤ 40 years at inclusion.

  5. Performance status: Lansky Play score (for patients ≤ 16 years of age) or Karnofsky score (for patients > 16 years of age) ≥ 70%.

  6. Life expectancy expected ≥ 4 months.

  7. - For Phase I exclusively, patients must have radiographically documented evaluable or measurable progressive disease by CT-scan, IRM or PET-scan 18F-FDG (measure of SUL and extension).

    - For Phase II exclusively, patients must have radiographically documented measurable and evaluable progressive disease. At least one site of disease might be measurable as follows: i. CT-scan, physical exam ≥10 mm ii. Chest X-ray ≥20 mm iii. Lymph node short axis ≥10 mm iv. Bone and marrow invasion on PET-scan FDG (measure of SUL and extension) All radiology studies must be performed between 7 and 28 days before the first dose of study treatment (C1D1).

  8. Adequate cardiac function with a shortening fraction ≥29% and left ventricular ejection fraction ≥50% at baseline (between 7 and 28 days before the first dose of study treatment (C1D1)), as determined by echocardiography.

  9. Adequate organ function within 21 days prior to first dose of study treatment:

    Hematologic criteria:

  10. Peripheral absolute neutrophil count (ANC) ≥1.0 × 109/L (unsupported),

  11. Absolute granulocytes ≥1.0 × 109/L,

  12. Platelets ≥100 × 109/L (unsupported),

  13. INR (International normalized ratio) ≤1.5 and aPTT (activated partial thromboplastin time) within normal limits.

    Biochemistry:

  14. Serum creatinine ≤1.5 x upper limit of normal (ULN) for age or creatinine clearance (CKD-EPI/Schwartz) ≥ 60 mL/min/1.73 m2,

  15. Total bilirubin ≤1.5 x ULN (≤3.0 x ULN for patients with Gilbert's syndrome),

  16. Alanine aminotransferase (ALT)/Serum glutamic pyruvic transaminase (SGPT) ≤2.5 × ULN and Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) ≤2.5 × ULN, except in patients with documented tumor involvement of the liver who must have ALT/SGPT and AST/SGOT ≤5 x ULN.

  17. Females of childbearing potential (WOCBP) must have a negative serum pregnancy test within 72 hours prior to first dose of study treatment.

  18. Sexually active WOCBP must agree to use a highly effective contraception method during the study treatment and for at least 6 months after the last study treatment administration.

    -Sexually active male patients must agree to use condoms during the study and at least 3 months after the last study treatment administration. Acceptable contraception methods are listed in X.1 Contraception.

  19. Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted, according to local, regional or national guidelines.

  20. Patients able to comply with study procedures, scheduled follow-up and with management of toxicity.

  21. Patient affiliated to a social security regimen or beneficiary of the same according to local requirement

Exclusion Criteria:

  1. Absence of tumor target(s): for Phase I: absence of visible and evaluable target; for Phase II: absence of evaluable target.

  2. Prior administration of mTOR inhibitors.

  3. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., chronic inflammatory bowel disease, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).

  4. Clinically significant uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality), congestive heart failure > class II NYHA with 12 months of screening, unstable angina or new-onset angina.

  5. Prior medical history of uncontrolled hypertension defined as follow:

    1. Patients aged ≤ 17 years: greater than 95th percentile systolic and diastolic blood pressure based on age and weight which is not controlled by one anti-hypertensive medication.
    2. Patients aged > 17 years: systolic blood pressure > 150mmHg and/or diastolic > 90 mmHg that is not controlled by one anti-hypertensive medication.
  6. Thrombotic or embolic events within the past 6 months.

  7. Evidence of interstitial lung disease.

  8. Non-controlled hyperlipidemia: At fasting: Serum cholesterol >3 g/L or 7.75mmol/L and Triglycerides >2.5 ULN).

  9. Constitutional abnormality of coagulation and/or hemostasis.

  10. Type I diabetes or non-controlled diabetes (fasting glycemia >1.5 ULN).

  11. Active viral hepatitis (serologically Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV)) or known human immunodeficiency virus (HIV) infection or any other uncontrolled active clinically serious infection of grade ≥2 defined by CTCAE v6.0.

  12. Serious non-healing wound, ulcer, or bone fracture at enrolment.

  13. Presence of any persistent grade ≥2 treatment-related toxicity with the exception of lymphopenia of any grade, alopecia, ototoxicity or peripheral neuropathy.

  14. Systemic anticancer therapy within 21 days of the first study dose or 5 times its half-life, whichever is less.

  15. Previous myeloablative therapy with autologous hematopoietic stem cell rescue within 8 weeks of the first dose of study treatment.

  16. Radiotherapy (non-palliative) within 21 days prior to the first study dose.

  17. Major surgery or significant traumatic injury within 21 days of the first study dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48-hour interval must be maintained before the first dose of the investigational drug is administered.

  18. History of another malignancy or any medical condition which in the opinion of the principal investigator could represent a risk for the patient or adversely affect the study objectives.

  19. Current therapeutic anticoagulation with Vitamin K antagonists.

  20. Concomitant treatment with medications or substances that are inhibitors or inducers of cytochrome CYP450 3A4.

  21. Concomitant treatment with corticosteroids within 14 days prior to the first dose of study treatment.

  22. Known hypersensitivity to any study drugs or components of the formulation.

  23. Pregnant or nursing lactating females.

  24. Vaccinated with live, attenuated vaccines, within 4 weeks of the first dose of study drug.

  25. Participation in other interventional clinical trials.

  26. Patient who has difficulty reading or understanding French

  27. Patient receiving government medical aid (Aide Médicale d'Etat - AME).

  28. Incompetent participant (subject to a legal protection measure: curatorship, guardianship, future protection mandate, family habilitation).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Experimental arm

In Phase I, the dose escalation part will determine the maximum tolerated dose (MTD) of Dinutuximab beta in combination with fixed doses of Sirolimus and Irinotecan. For the Phase II part, the RP2D (recommended phase 2 dose) dose of Dinutuximab beta will be used in combination with the fixed dose of Sirolimus and Irinotecan combination.

The dose escalation (Phase I) part will determine the maximum tolerated dose (MTD) of Dinutuximab beta in combination with fixed doses of Sirolimus and Irinotecan (RAPIRI), as follows: iv. irinotecan on days 1 and 15 (125 mg/m2/dose) and oral Sirolimus given daily (1.5 mg/m2/dose) in 28-day courses. The Dinutuximab beta will be administered for 4 days from D1 to D4 and D15 to D18 as an iv. infusion. The combination of Sirolimus and Irinotecan plus Dinutuximab beta will be during the 6 first courses and from C7, the Sirolimus and Irinotecan combination will be administered as detailed above during the last 6 months or courses.

For the Phase II part, the RP2D dose of Dinutuximab beta will be used in combination with the fixed dose of Sirolimus and Irinotecan combination as described above. The same scheme during the 12 months will be planned: triple combination during 6 courses and then a maintenance with 6 courses of Sirolimus and Irinotecan treatment.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Phase 1: Determination of the maximum tolerated dose (MTD) of Dinutuximab beta, given in combination with iv. Irinotecan (day 1 and day 15) and daily oral Sirolimus
기간: From the first dose of treatment to the end of cycle 1 (28 days)
From the first dose of treatment to the end of cycle 1 (28 days)
Phase 2:
기간: At or before 16 weeks after the first dose of study drug

Determination of the Progression Free Survival rate, based on investigator assessment per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) version 1.1 and/or PET Response Criteria In Solid Tumor version 1.0 (PERCIST 1.0).

At or before 16 weeks after the first dose of study drug

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Natacha ENTZ WERLE, MD PhD, Hopitaux Universitaires de Strasbourg

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 1일

기본 완료 (추정된)

2031년 2월 1일

연구 완료 (추정된)

2033년 2월 1일

연구 등록 날짜

최초 제출

2026년 8월 31일

QC 기준을 충족하는 최초 제출

2026년 9월 28일

처음 게시됨 (실제)

2026년 10월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다